Non-acute decompensation of cirrhosis (NAD) represents a distinct clinical state characterized by elevated cell death markers and moderate prognosis. Identifying predictors such as ascites severity and biomarkers Gasdermin-D and RIPK3 may guide timely interventions to prevent progression to acute decompensation and reduce mortality.